This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
iBio Inc IBIO
$1.19
▼ -0.83%
($-0.01)
Open
$1.23
Prev Close
$1.20
Day Range
$1.15 – $1.24
52W Range
$0.78 – $3.82
Market Cap
$72.42M
Beta
1.42
EPS (TTM)
$-0.54
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2008-08-18 |
| Shares Out. | 49,680,000 |
| Website | ibioinc.com/ ↗ |
| Phone | 18009279800 |
| Employees | 23 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$10.6M |
| Free Cash Flow | -$23.8M |
| Total Assets | $99.1M |
| Total Liabilities | $13.4M |
| Equity | $85.7M |
About iBio Inc
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
iBio Inc is a publicly traded company under the ticker symbol IBIO on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)